In August 2017, Sanofi's acquisition of Proteien Sciences was finalized with the transaction in major part, it would seem, due to the smaller firm's strong position the flu vaccine space, More than once in earlier years, the firm had been indicated as being acquired only to have the deal(s) fall through. Protein Sciences Corporation (PSC) had been a biopharmaceutical service company focused on proprietary vaccine development and manufacturing, as well as the development of antigens for scientific research. PSC used the Baculovirus Expression Vector System (BEVS) on a commercial scale. Applications of the BEVS include prophylactic vaccines, therapeutic vaccines, gene therapy, and biologics. The company had partnered with pharmaceutical, biotechnology and genomics companies aiming to proceed from a gene target to a commercial vaccine, therapeutic, or screening molecule. The company's products include the Flublok influenza vaccine, the Diamyd therapeutic vaccine for type I diabetes, and the Glybera gene therapy for lipoprotein lipase deficiency. The cmpany is also developing candidate vaccine for possible pandemic-causing viruses such as the H1N1 swine and H5N1 and H7N9 avian influenza viruses and for Severe Acute Respiratory Syndrome (SARS).
